Business Wire

NY-IFF

22.5.2023 12:56:26 CEST | Business Wire | Press release

Share
IFF Highlights Progress Against ESG+ Strategy in New Do More Good Report

IFF (NYSE:IFF) today released its 2022 Do More Good Report, which highlights performance and progress against goals set forth in the Do More Good Plan, the Company’s environmental, social, governance, plus sustainable solutions (or ESG+) strategy and roadmap that activates its purpose of applying science and creativity for a better world.

The Do More Good Report: IFF’s 2022 ESG+ Progress, describes the first full year of performance and progress as One IFF following the 2021 merger with DuPont’s Nutrition & Biosciences division. IFF will hold a live webcast to discuss the Company’s Do More Good Plan and goals, 2022 ESG+ results, and 2023 sustainability outlook on May 23, 2023, at 9:00 a.m. ET.

“When we launched our Do What Matters Most strategy in 2022, we committed to embedding ESG+ in all we do,” said Frank Clyburn, IFF CEO. “Our 2022 Do More Good Report illustrates the steps we’re taking to deliver on our commitments to address sustainable development imperatives. Our world-class R&D program and commitment to innovation fuels a pipeline of exciting sustainable solutions that are helping our customers reach their ESG goals and, in turn, responding to heightened consumer expectations on sustainability.”

The 2022 Do More Good Report is organized according to the four pillars of the Do More Good Plan, which reflect the areas where the Company can have the greatest positive impact in addressing the world’s most pressing sustainable development challenges: Sustainable Solutions; Climate & Planetary Health; Equity & Wellbeing; and Transparency & Accountability.

2022 performance highlights and achievements by IFF include:

  • Recognized externally for ESG leadership, including being named to the Dow Jones Sustainability Indices for the third consecutive time, and maintaining the 2022 EcoVadis platinum sustainability rating, placing IFF among the top 1% of companies assessed;
  • Enabled customers and consumers to save more CO2e than generated at IFF’s own manufacturing sites by accelerating the wider adoption of sustainable solutions in the marketplace, as documented by life cycle assessments;
  • Named to the CDP Climate A list for the eighth consecutive year and completed its first virtual power purchase agreement, expected to cover approximately 30% of the total electricity needs of its European sites when it becomes operational at full capacity in 2024;
  • Recertified as EDGE Move level globally for its commitment to gender parity, and included in the Bloomberg Gender-Equality Index for the second time;
  • Introduced a Global Parental Leave Policy that grants a minimum of 16 weeks of 100% paid leave for a new IFF parent, regardless of gender identity or expression;
  • Linked ESG performance metrics for reduction of greenhouse emissions and increases in company-wide gender representation to the Annual Incentive Plan Award for executive leaders, impacting 2022 variable compensation by 5%;
  • Completed updates to its Code of Conduct training and certification campaign, achieving a 99.8% acknowledgment rate among employees.

To learn more, visit iff.com/responsibilities and use #DoMoreGoodxIFF to follow the conversation on its social channels.

Webcast

IFF will hold a live webcast to discuss the Company’s Do More Good Plan, 2022 key performance metrics, progress against 2030 goals and 2023 outlook on May 23, 2023 at 9:00 a.m. ET., where Mr. Clyburn will be joined by Michael DeVeau, Senior Vice President, Corporate Finance and Investor Relations; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Ralf Finzel, Chief Operations Officer; Deborah Borg, Chief Human Resources, Diversity, Equity & Inclusion and Communications Officer; and Jennifer Johnson, General Counsel and Corporate Secretary. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com.

IFF invites investors, analysts and all IFF stakeholders to participate by phone by calling 1-404-975-4839 from the United States and toll-free from other locations by calling +1-833-470-1428. The access code for the conference call is 758853, and a listen-only webcast will be available at ir.iff.com. For those unable to listen to the live webcast, IFF will post a recorded version on the Company’s website approximately one hour after the event.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005421/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye